Opko

The diagnostic is being developed using a new peptoid-based technique for detecting disease-specific antibodies that could prove broadly useful as a protein biomarker discovery tool, said a researcher.

People in the News

Premium

Dale Pfost, Garry Menzel

For instance, Tacere Therapeutics received $488,958 in two grants, the first of which supports development of a new hepatitis C treatment, as well as a previously undisclosed eye-disease program.

The two areas, which have opportunities RXi's CEO called "tremendous" and "significant," have been well worn by rival drug companies making similar bets including Sirnaomics, TransDerm, and Quark Pharmaceuticals.

People in the News

Premium

Philip Frost

According to Opko, Schering-Plough is making the divestiture, which includes the phase II chemotherapy-related nausea and vomiting prophylactic rolapitant, in order to meet certain requirements for its expected merger with Merck.

According to Opko, the company focuses on "the representation, importation, commercialization, and distribution of pharmaceutical products, [over-the-counter] products, and medical devices for the government, private, and institutional markets."

The transaction "provides the company with additional financial resources to fund acquisitions and support bringing [its] projects and pipeline of novel drugs and products to market," according to Opko Chairman and CEO Phillip Frost.

The arrangement marks the latest step away from the RNAi field for Opko, which has signed a number of deals recently not involving the gene-silencing technology.

People in the News

Premium

Steven Rubin, Peter Garcia, Bruce York, Paul McDonnel, Joseph Kingsley

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.